Home

Advanced Cancer Therapies serves as a comprehensive forum to promote research, development and application of advanced cancer therapies. This event promotes education and the exchange of information among professionals regarding advanced cancer therapies. Abstract submissions are being accepted from July 15 – October 16, 2024. Your abstract proposals are an integral part of the Advanced Cancer Therapies. We want to ensure you have the opportunity to share your knowledge. Registration is now open! You can

Read the full article here

Source: s2.goeshow.com

Categories: Oncologists1, General Medicine News

Tweets with this article

Society of Surgical Oncology

Ready to showcase your research in Scottsdale? 🌟 Don’t miss your chance—register NOW for Advanced Cancer Therapies 2025 and submit your abstract today! https://t.co/Fbi8fImK5j https://t.co/jyhFslfShD

Preparation is Key to Tackle the Transition from Fellow to Attending Physician

A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.

OncLive.com December 29, 2024

Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC

Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides a brief overview on the Phase II trial (NCT02276443) of neoadjuvant…

VJ Oncology December 29, 2024

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

OncLive.com December 29, 2024

Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression

Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

OncLive.com December 29, 2024

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

OncLive.com December 29, 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

OncLive.com December 29, 2024

Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis

Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.

OncLive.com December 29, 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

OncLive.com December 29, 2024

Landmark Clinical Trial Shows Value of Immunotherapy for… : Oncology Times

An abstract is unavailable.

Oncology Times December 28, 2024

Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.

OncLive.com December 28, 2024

Related Articles